Understand the source comparison
Can AOD-9604 Be Cycled Like Other Research Compounds: Comparison
Researchers evaluating whether to cycle aod-9604 like other research compounds often compare it to anabolics, full-length hGH, and other peptide fragments. The table below shows how cycling necessity differs across compound classes. AOD-9604 Beta-3 adrenergic
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Researchers evaluating whether to cycle aod-9604 like other research compounds often compare it to anabolics, full-length hGH, and other peptide fragments. The table below shows how cycling necessity differs across compound classes.
- AOD-9604
- Beta-3 adrenergic agonism (adipocytes)
- None. Doesn't bind GH receptors
- Optional (logistical, not physiological)
- 12–24 weeks continuous or 12 on / 4–8 off
- Cycling isn't required to preserve efficacy or prevent adaptation. It's a budget or study design choice, not a biological necessity
- Full-Length hGH
- Somatotropic receptor binding
- High. Suppresses pituitary GH secretion within weeks
- Mandatory for long-term use
- 8–12 weeks on / 8–12 weeks off
- Cycling is required to restore endogenous pulsatile GH production and prevent receptor desensitisation that reduces IGF-1 response
- Anabolic Steroids
- Androgen receptor binding
- Severe. Shuts down HPG axis
- Mandatory
- 8–16 weeks on / 8–16 weeks off + PCT
- Cycling is non-negotiable to restore natural testosterone production and prevent permanent hypogonadism
- CJC-1295 / Ipamorelin
- GHRH and ghrelin receptor agonism
- Moderate. Can blunt natural GH pulses over time
- Recommended but not absolute
- 12–16 weeks on / 4–8 weeks off
- Cycling helps preserve endogenous GH pulsatility, though these peptides are less suppressive than exogenous hGH
- Thyroid Hormones (T3/T4)
- Thyroid receptor binding
- High. Suppresses TSH and endogenous thyroid output
- Mandatory for extended use
- 6–12 weeks on / 4–8 weeks off
- Cycling prevents thyroid atrophy and allows the hypothalamic-pituitary-thyroid axis to recover baseline function